2-(tert-butyl) 1-methyl isoindoline-1,2-dicarboxylate | 444607-92-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-(tert-butyl) 1-methyl isoindoline-1,2-dicarboxylate
• 英文别名: O2-tert-butyl O1-methyl isoindoline-1,2-dicarboxylate；O-tert-butyl methyl isoindoline-1,2-dicarboxylate；2-tert-butyl-1-methyl-1,3-dihydro-2H-isoindole-1,2-dicarboxylate；1,3-dihydro-2H-isoindole-1,2-dicarboxylic acid, 2-tert-butyl ester, 1-methyl ester；N-BOC-1,3-dihydro-2H-isoindole-1-carboxylic acid, methyl ester；N-BOC-1,3-dihydro-2H-isoindol-1-carboxylic acid, methyl ester；2-O-tert-butyl 1-O-methyl 1,3-dihydroisoindole-1,2-dicarboxylate
• CAS: 444607-92-5
• 化学式: C₁₅H₁₉NO₄
• 分子量: 277.32
• InChiKey: BAXYISQCVRCCJM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  55.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(tert-butyl) 1-methyl isoindoline-1,2-dicarboxylate 在 N-甲基吗啉 、 盐酸 、 甲醇 、 lithium hydroxide 、 水 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 36.0h， 生成 2-(5-chloro-2,4-bis-methoxymethoxybenzoyl)-2,3-dihydro-1H-isoindole-1-carboxylic acid
  参考文献：
  名称：

  WO2006/117669

  摘要：

  公开号：
• 作为产物：
  描述：

  1-异吲哚啉羧酸盐酸盐(1:1) 在 4-二甲氨基吡啶 、 氯化亚砜 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 2-(tert-butyl) 1-methyl isoindoline-1,2-dicarboxylate
  参考文献：
  名称：

  通过顺序氮丙啶环形成/打开将异吲哚啉立体定向扩环骨架重排为四氢异喹啉

  摘要：

  DOI：

  10.3987/com-18-s(f)98

文献信息

• Piperidinyl-alpha-aminoamide modulators of chemokine receptor activity
  申请人：Zhou Cangyou

  公开号：US20050250814A1

  公开（公告）日：2005-11-10

  The present invention is directed to compounds of the formula I: (wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , W, X, Z, m and n are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptor CCR-2.

  本发明涉及具有以下式I的化合物：（其中R1、R2、R3、R4、R5、R6、W、X、Z、m和n在此处定义），这些化合物可用作趋化因子受体活性的调节剂。特别是，这些化合物可用作趋化因子受体CCR-2的调节剂。
• N-arylsulfonyl aryl aza-bicyclic derivatives as potent cell adhesion inhibitors
  申请人：——

  公开号：US20020193399A1

  公开（公告）日：2002-12-19

  Compounds of Formula I are antagonists of VLA-4 and/or alpha4/beta7, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of AIDS-related dementia, allergic conjunctivitis, allergic rhinitis, Alzheimer's disease, asthma, atherosclerosis, autologous bone marrow transplantation, certain types of toxic and immune-based nephritis, contact dermal hypersensitivity, inflammatory bowel disease including ulcerative colitis and Crohn's disease, inflammatory lung diseases, inflammatory sequelae of viral infections, meningitis, multiple sclerosis, multiple myeloma, myocarditis, organ transplantation, psoriasis, pulmonary fibrosis, restenosis, retinitis, rheumatoid arthritis, septic arthritis, stroke, tumor metastasis, uveititis, and type I diabetes.

  化合物I的拮抗剂是VLA-4和/或alpha4/beta7，因此在抑制或预防细胞粘附和细胞粘附介导的病理过程中是有用的。这些化合物可以制成药物组合物，适用于治疗艾滋病相关痴呆、过敏性结膜炎、过敏性鼻炎、阿尔茨海默病、哮喘、动脉粥样硬化、自体骨髓移植、某些类型的毒性和免疫性肾炎、接触性皮肤过敏、炎症性肠病包括溃疡性结肠炎和克罗恩病、炎症性肺部疾病、病毒感染的炎症后遗症、脑膜炎、多发性硬化症、多发性骨髓瘤、心肌炎、器官移植、银屑病、肺纤维化、再狭窄、视网膜炎、类风湿性关节炎、脓毒性关节炎、中风、肿瘤转移、葡萄膜炎和I型糖尿病。
• [EN] ACYL ISOINDOLINE DERIVATIVES AND ACYL ISOQUINOLINE DERIVATIVES AS ANTI-VIRAL AGENTS<br/>[FR] DERIVES D'ACYLE ISOINDOLINE ET D'ACYLE ISOQUINOLINE UTILISES COMME AGENTS ANTIVIRAUX
  申请人：GLAXO GROUP LTD

  公开号：WO2004096774A1

  公开（公告）日：2004-11-11

  Anti-viral agents of Formula (I) wherein: R3 represents aryl or heteroaryl; R4 represents one or two substituents independently selected from hydrogen, C 1-6alkyl, halo, ORA , C(O)NRBRC, C(O)RD, CO2H, CO2RD, NRBRC, NRE C(O)RD, NRECO2RD, NREC(O)NRFRG, NRESO2RD, SO2NRFRG, SO2RD, nitro, cyano, heterocyclyl, heteroaryl, aryl, arylalkyl heteroarylalkyl or CF3; R5 and R6 independently represent hydrogen, C1-6alkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; n represents 0 or 1; when n represents 0, R1 represents C(O)RH and R2 represents C1-6alkyl, heterocyclylalkyl, arylalkyl or heteroarylalkyl; when n represents 1, either i) R1 represents C(O)RH; R2 represents C1-6alkyl, heterocyclylalkyl, arylalkyl or heteroarylalkyl; and R7 and R8 independently represent hydrogen, C1-6alkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; or ii) R1 and R2 independently represent hydrogen, C1-6alkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; R7 represents C(O)RH; and R8 represents C1-6alkyl, heterocyclylalkyl, arylalkyl or heteroarylalkyl; RA represents hydrogen, C1-6alkyl, arylalkyl, heteroarylalkyl, aryl or heteroaryl; RB and RC independently represent hydrogen, C1-6alkyl, aryl or heteroaryl; or RB and RC together with the nitrogen atom to which they are attached form a 5 or 6 membered saturated cyclic group; RD is selected from the group consisting of C1-6alkyl, aryl, heteroaryl, arylalkyl, and heteroarylalkyl; RE represents hydrogen or C1-6alkyl; RF and RG are independently selected from the group consisting of hydrogen, C1-6alkyl, aryl, heteroaryl, arylalkyl, and heteroarylalkyl; or RF and RG together with the nitrogen atom to which they are attached form a 5 or 6 membered saturated cyclic group; RH represents hydroxy or NRBRC; and salts, solvates and esters thereof; provided that when RH is hydroxy, which is esterified to form -OR where R is selected from straight or branched chain alkyl, aralkyl, aryloxyalkyl, or aryl, then R is other than tert-butyl. Processes for their preparation and methods of using them in HCV treatment are provided.

  Formula（I）的抗病毒剂，其中：R3代表芳基或杂环芳基；R4代表一个或两个取代基，独立选择自氢、C1-6烷基、卤素、ORA、C（O）NRBRC、C（O）RD、CO2H、CO2RD、NRBRC、NREC（O）RD、NRECO2RD、NREC（O）NRFRG、NRESO2RD、SO2NRFRG、SO2RD、硝基、氰基、杂环烷基、杂环芳基、芳基、芳基烷基、杂环芳基烷基或CF3；R5和R6独立代表氢、C1-6烷基、芳基、杂环芳基、芳基烷基或杂环芳基烷基；n代表0或1；当n代表0时，R1代表C（O）RH，R2代表C1-6烷基、杂环烷基、芳基烷基或杂环芳基烷基；当n代表1时，要么i）R1代表C（O）RH；R2代表C1-6烷基、杂环烷基、芳基烷基或杂环芳基烷基；且R7和R8独立代表氢、C1-6烷基、芳基、杂环芳基、芳基烷基或杂环芳基烷基；或ii）R1和R2独立代表氢、C1-6烷基、芳基、杂环芳基、芳基烷基或杂环芳基烷基；R7代表C（O）RH；且R8代表C1-6烷基、杂环烷基、芳基烷基或杂环芳基烷基；RA代表氢、C1-6烷基、芳基烷基、杂环芳基烷基、芳基或杂环芳基；RB和RC独立代表氢、C1-6烷基、芳基或杂环芳基；或RB和RC与它们连接的氮原子一起形成5或6个成员饱和环；RD选自由C1-6烷基、芳基、杂环芳基、芳基烷基和杂环芳基烷基组成的群体；RE代表氢或C1-6烷基；RF和RG独立选择自氢、C1-6烷基、芳基、杂环芳基、芳基烷基和杂环芳基烷基组成的群体；或RF和RG与它们连接的氮原子一起形成5或6个成员饱和环；RH代表羟基或NRBRC；以及其盐、溶剂化合物和酯；但是当RH是羟基时，酯化形成-OR，其中R选择自直链或支链烷基、芳基烷基、芳氧基烷基或芳基，那么R不是叔丁基。提供了它们的制备方法以及在HCV治疗中使用它们的方法。
• N-arylsulfonyl aza-bicyclic derivatives as potent cell adhesion inhibitors
  申请人：——

  公开号：US20030008861A1

  公开（公告）日：2003-01-09

  Compounds of Formula I are antagonists of VLA-4 and/or alpha4/beta7, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of AIDS-related dementia, allergic conjunctivitis, allergic rhinitis, Alzheimer's disease, asthma, atherosclerosis, autologous bone marrow transplantation, certain types of toxic and immune-based nephritis, contact dermal hypersensitivity, inflammatory bowel disease including ulcerative colitis and Crohn's disease, inflammatory lung diseases, inflammatory sequelae of viral infections, meningitis, multiple sclerosis, multiple myeloma, myocarditis, organ transplantation, psoriasis, pulmonary fibrosis, restenosis, retinitis, rheumatoid arthritis, septic arthritis, stroke, tumor metastasis, uveititis, and type I diabetes.

  公式I的化合物是VLA-4和/或alpha4/beta7的拮抗剂，因此在抑制或预防细胞黏附和细胞黏附介导的病理过程中具有用处。这些化合物可以制成药物组合物，适用于治疗艾滋病相关痴呆、过敏性结膜炎、过敏性鼻炎、阿尔茨海默病、哮喘、动脉粥样硬化、自体骨髓移植、某些类型的毒性和免疫性肾炎、接触性皮肤过敏、炎症性肠病包括溃疡性结肠炎和克罗恩病、炎症性肺部疾病、病毒感染的炎症后遗症、脑膜炎、多发性硬化症、多发性骨髓瘤、心肌炎、器官移植、银屑病、肺纤维化、再狭窄、视网膜炎、类风湿性关节炎、败血症性关节炎、中风、肿瘤转移、葡萄膜炎和I型糖尿病的治疗。
• Discovery of isoindoline and tetrahydroisoquinoline derivatives as potent, selective PPARδ agonists
  作者：Christopher A. Luckhurst、Linda A. Stein、Mark Furber、Nicola Webb、Marianne J. Ratcliffe、Gary Allenby、Sara Botterell、Wendy Tomlinson、Barrie Martin、Andrew Walding

  DOI：10.1016/j.bmcl.2010.10.117

  日期：2011.1

  We describe the discovery of small molecule isoindoline and tetrahydroisoquinoline derivatives as agonists of human peroxisome proliferator-activated receptor δ (PPARδ that displayed excellent selectivity over the PPARα and PPARγ subtypes. Compound demonstrated efficacy in upregulation of PDK4 in human primary myotubes, a biomarker for increased fatty acid oxidation.

  我们描述了小分子异吲哚啉和四氢异喹啉衍生物作为人过氧化物酶体增殖物激活受体 δ（PPARδ 的激动剂）的发现，对 PPARα 和 PPARγ 亚型表现出优异的选择性。化合物显示出上调人原代肌管中 PDK4 的功效，PDK4 是增加的生物标志物。脂肪酸氧化。